SAN DIEGO--(BUSINESS WIRE)--f5 Therapeutics Incorporated, a privately-held pharmaceutical company developing small-molecule protein degraders via the NExMods™ platform, today announced the appointment of Paul Pockros, MD to its Scientific Advisory Board. He is the President and Founder of SC Liver Research Consortium, LLC, an organization of physicians specializing in clinical research that focuses on Phase I-IV clinical hepatology, gastroenterology, and oncology trials. Dr. Pockros has held numerous leadership roles in his distinguished career at Scripps Clinic including Director of the Liver Disease Center and Director of Clinical Research of the Scripps Translational Science Institute, Chief of Staff at Scripps Green Hospital, Medical Director of the Liver Transplantation Program, and Head of the Division of Gastroenterology/Hepatology.
“We are excited to begin building our Scientific Advisory Board with Dr. Pockros as our founding member,” said Gary Choy, Co-Founder, Chair, and CEO of f5 Therapeutics Inc “He has been a pioneer in the development of multiple innovative therapies helping to improve liver disease outcomes.”
“I am excited to contribute to the mission of f5 Therapeutics,” said Dr. Pockros, “Protein degradation offers the ability to target previously undruggable disease driving proteins, such as transcription factors. This novel approach may unlock the potential for better therapeutics targeting liver cancer, liver fibrosis, and NASH. I look forward to working with f5’s team to optimize their platform technology.”
In addition to his clinical practice, Dr. Pockros is a principal investigator for a number of studies at Scripps. He has contributed over 300 published manuscripts and abstracts in peer-reviewed journals on topics such as chronic viral hepatitis, liver transplantation, complications of cirrhosis, diagnostic tests for liver disorders, and alcoholic, metabolic, and fatty liver diseases. Dr. Pockros received his medical degree and completed his residency in internal medicine at the University of Southern California School of Medicine, followed by a fellowship in hepatology at Rancho Los Amigos Medical School and a fellowship in gastroenterology at Scripps Clinic.
About f5 Therapeutics Incorporated
f5 Therapeutics is a privately held pharmaceutical company dedicated to the development of “First-in-Class” small molecules for the treatment of diseases with high unmet medical need. f5 Therapeutics continues to evolve targeted protein degradation to transform the landscape of drug discovery by utilizing the cell’s normal protein regulation systems to remove disease causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (Neosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering impactful medicines to patients across diverse therapeutic areas including oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. To learn more: http://www.f5therapeutics.com